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Abstract
Background/Aims: Lubeluzole is a benzothiazole derivative that has shown neuroprotective 
properties in preclinical models of ischemic stroke. However, clinical research on lubeluzole 
is now at a standstill, since lubeluzole seems to be associated with the acquired long QT 
syndrome and ventricular arrhythmias. Since the cardiac cellular effects of lubeluzole have not 
been described thus far, an explanation for the lubeluzole-induced QT interval prolongation 
is lacking. Methods: We tested the affinity of lubeluzole, its enantiomer, and the racemate for 
hERG channel using the patch-clamp technique. We synthesized and tested two simplified 
model compounds corresponding to two moieties included in the lubeluzole structure. 
The obtained experimental results were rationalized by docking simulation on the recently 
reported cryo-electron microscopy (cryo-EM) structure of hERG. Group efficiency analysis was 
performed in order to individuate the fragment most contributing to binding. Results: We 
found that lubeluzole and its R enantiomer are highly potent inhibitors of human ether-a-
go-go-related gene (hERG) channel with an IC50 value of 12.9 ± 0.7 nM and 11.3 ± 0.8 nM, 
respectively. In the presence of lubeluzole, steady-state activation and inactivation of hERG 
channel were shifted to more negative potentials and inactivation kinetics was accelerated. 
Mutations of aromatic residues (Y652A and F656A) in the channel inner cavity significantly 
reduced the inhibitory effect of lubeluzole. Molecular docking simulations performed on the 
near atomic resolution cryo-electron microscopy structures of hERG supported the role of Y652 
and F656 as the main contributors to high affinity binding. Group efficiency analysis indicated 
that both 1,3-benzothiazol-2-amine and 3-aryloxy-2-propanolamine moieties contribute to 
drug binding with the former giving higher contribution. Conclusions: This study suggests 
the possibility to modulate lubeluzole hERG blockade by introducing suitable substituents 
onto one or both constituting portions of the parent compound in order to either reduce 
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potency (i. e. torsadogenic potential) or potentiate affinity (useful for class III antiarrhythmic 
and anticancer agent development).
IntroductionLubeluzole [(S-1), Fig. 1A] is a benzothiazole derivative that has shown neuroprotective properties in preclinical models of ischemic stroke. The exact mechanism of neuroprotection exerted by lubeluzole, in both clinical and experimental models of cerebral ischemia [1], is not 
clearly defined. In fact, the drug seems to modulate in vitro different molecular pathways. It inhibits the signal transduction mechanisms of nitric oxide (NO) [2], the release of glutamate [3, 4], and blocks Q-type voltage-gated Ca2+ channels [5]. In addition, the drug blocks voltage-gated sodium channels in brain neurons and cardiomyocytes [6, 7], but it has been recently reported that its neuroprotective action is not triggered by sodium channel inhibition [8]. Since lubeluzole inhibits neuronal cyclic guanosine monophosphate (cGMP) accumulation, it has been proposed that inhibition of neuronal nitric oxide pathways may represent the main mechanism of neuroprotection [2]. The anti-ischemic activity of lubeluzole has also been related to calmodulin (CaM) activity and the counteraction of osmotic stress (mechanism 
associated with the release of the active amino acid taurine) [9]. The affinity of lubeluzole for CaM and its inhibiting activity on Ca2+/CaM-dependent kinase II at the low micromolar level have recently been reported [10].Moreover, lubeluzole has shown reductions of infarct volume and improved neurological function in a photothrombotic occlusion model in rats [11], and in a conventional permanent Middle Cerebral Artery Occlusion (MCAO) model also in rats [12], although the neuroprotective effects in the MCAO model were lost if administration was delayed by more than 30 minutes after onset of ischaemia. Recently, it has been demonstrated that lubeluzole synergizes with both doxorubicin and paclitaxel on human ovarian adenocarcinoma and lung carcinoma cells, respectively, over a wide concentration range (0.005-5 µM) [13]; the lowest concentration was at least 40 times lower than human plasma concentrations clinically 
relevant for the anti-ischemic activity [14]. In view of the above considerations, lubeluzole has been recently included in a list of sodium channel blocker candidates to repositioning [15].Despite these promising in vitro and in vivo results, clinical research on lubeluzole is 
now at a standstill, since lubeluzole seems to be associated with a significant increase of 
heart-conduction disorders. In particular, therapeutic lubeluzole concentrations increase the action potential duration, thus causing the prolongation of the QT interval of the electrocardiogram in some of the treated patients [16, 17]. The Cochrane systematic review 
of lubeluzole trials [18], involving 3510 patients in five trials, confirmed lack of benefit and 
also significant excess risk of cardiac conduction abnormalities at all doses, including the 10 mg dose employed in most trials.The prolongation of QT waves, caused by cardiotoxic drugs, has mainly been related to the inhibition of IKr, the current carried by the human ether-a-go-go-related gene (hERG) channel [19]. Based on this experimental evidence, as well as the finding that specific mutations in hERG are responsible for one form of congenital long-QT syndrome [20], the hERG channel assay is now considered an important antitarget in the preclinical safety testing process [21].Since the cardiac cellular effects of lubeluzole have not been described thus far, an 
explanation for the lubeluzole-induced QT interval prolongation is lacking. In this article 
we i) tested the affinity of lubeluzole, its enantiomer, and the racemate for hERG channel using the patch-clamp technique; ii) investigated the hERG channel residues involved in the binding of lubeluzole; iii) searched for the main molecular determinants of lubeluzole block 
of hERG. This latter goal was pursued by designing, preparing, and testing two simplified model compounds corresponding to two moieties included in the lubeluzole structure. The obtained experimental results were rationalized by docking simulation on the recently 
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reported cryo-electron microscopy (cryo-EM) structure of hERG [22]. Group efficiency analysis was performed in order to identify the fragment most contributing to binding.
Materials and Methods
ChemistryLubeluzole [(S)-1], its R enantiomer [(R)-1], the corresponding racemate, and N-methyl-N-piperidin-4-yl-1, 3-benzothiazol-2-amine (3) (Fig. 1A) were prepared following or adapting previously reported procedures [23, 13]. Compound 3 was then converted into its hydrochloride salt by treatment with a 
few drops of 2 M HCl and azeotropically removing water. (S)-1-(3, 4-difluorophenoxy)-3-(piperidin-1-yl)propan-2-ol [(–)-(S)-2] (Fig. 1A) was obtained following a previously reported procedure [8].
Maintenance of mammalian cell lines and cell transfectionPatch-clamp studies were carried out on Human Embryonic Kidney (HEK) 293 cells stably transfected 
with hERG1a isoform, (DI.V.A.L. Toscana srl, Italy) and Chinese Hamster Ovary (CHO) cells transiently expressing hERG mutants. For heterologous protein expression, cells were plated in 6-well cell culture dishes with 2 mL growth medium, 24 h before transfection. Cells were transiently transfected with hERG 
mutants using TurboFect transfection reagent (Thermo Scientific). EGFP fluorescence was used as markers of successful transfection. Electrophysiology studies were performed 48/72 hr after transfection.
Electrophysiological recordingsElectrophysiological recordings were performed using the whole-cell mode of the patch-clamp technique. The extracellular solution used for patch-clamp recordings had the following composition: 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM Glucose, 10 mM HEPES, pH 7.4 with NaOH. A modified ‘high K+’ solution (containing 94 mM KCl and 50 mM NaCl) was used to study T623A and F656A hERG channel mutants [24-26]. The pipette contained: 145 mM KCl, 10 mM EGTA, 1 mM MgCl2, 2 mM Mg-ATP, 10 mM HEPES, pH 7.30 with KOH. Solutions were applied to the cell via a gravity-fed perfusion system 
(VC-6 Six Channel Valve Controller, Warner Instruments). Patch-clamp electrodes were pulled from Sutter 
capillary glass (Novato, CA) on a Flaming/Brown type puller (Sutter P-87), and fire polished to 3-4 MΩ resistance, using a microforge (Narishige). To minimize voltage errors, 50–70% of the series resistance was electronically compensated. Patch-clamp recordings of cell cultures were carried out at room temperature 
48h after transfection. For recordings a Multiclamp 200B amplifier (Molecular Devices, Inc, Sunnyvale, CA) 
and Digidata 1440 data acquisition board (Molecular Devices, Inc, Sunnydale, CA) with pCLAMP 10 software 
(Molecular Devices, Inc, Sunnyvale, CA) were used. Data analysis was performed using Origin 8.0 (OriginLab Corporation, Northampton, MA).
Molecular modelingLubeluzole was docked into the near atomic resolution cryo-EM structures of the hERG wild type 
(WT) (pdb: 5VA1, 3.7 Å resolution) and S631A mutant channels (pdb: 5VA3, 4.0 Å resolution) using the 
program Gold4.0.1 (Cambridge DataCentre, Cambridge, UK, [27]). Protein flexibility was realized including 20 snapshots derived from unbiased 500 ns all-atom Molecular Dynamics simulations (for all online suppl. material, see www.karger.com/doi/10.1159/000488169, Suppl. methods).  The binding site radius was 
set to 20 Å around the geometric centers of Y652, which lead to a selection including all experimentally observed hERG binding determinants [20, 28, 29], as well as the hydrophobic pouches behind the selectivity 
filter [22]. 100, 000 operations of the GOLD genetic algorithm were used to dock both enantiomers. 100 docking poses per run were stored, with the 20 highest ranked poses analyzed in detail.
Results
Effect of lubeluzole on WT hERGTo investigate the effect of lubeluzole [(S)-1], its R enantiomer [(R)-1], and the racemic mixture (Fig. 1A) on hERG potassium channels, patch-clamp experiments were performed on HEK cells heterologously expressing the hERG channel. To elicit the activating outward 
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-80 mV to 0 mV (3 s in du-ration) was applied. Tail current was evoked by re-
polarizing to -40 mV for 3 s. Successive command pulses were applied at 10-second intervals.Fig. 1B shows represen-
tative recordings of WT IhERG in the absence (control) and in the presence of lubeluzole 
(100 nM). In the presence of lubeluzole, the tail current was strongly reduced and the 
IhERG block induced by lubelu-zole was almost irreversible, even after 10 min. of perfu-sion with the control solu-tion (Fig. 1C). The inhibition caused by lubeluzole, its R enantiomer, and the racemic mixture, at each concentra-tion, was calculated using Eq. (1) (see online suppl. materi-al) and the mean values, after normalization, were plotted as shown in Fig. 1D. Fitting 
the data in Fig. 1D with the Hill equation [Eq. (2), (see online suppl. material)] yielded an IC50 
of 12.9 ± 0.7 nM and a Hill slope (nH) of 0.84 ± 0.05, for lubeluzole; an IC50 of 11.3 ± 0.8 nM 
and a nH of 0.79 ± 0.04 for its R enantiomer; an IC50 of 11.1 ± 0.4 nM and a nH of 1.1 ± 0.03 for 
the racemic mixture (Fig. 1D). Since no statistically significant differences between IC50 val-ues were obtained, we conclude that lubeluzole binds hERG channel in a non-stereoselective manner.Due to the known low expression and altered kinetic properties of some hERG mutants (in particular T623A and F656A clones), we measured the inward current of the T623A and F656A mutants in high (94 mM) external K+ solution, since the external K+ concentration increase is aimed to maximize the inward tail currents [25, 26, 30]. Consequently, we tested lubeluzole block of wild-type IhERG under similar experimental conditions, to examine whether 
a change in the ionic conditions affects hERG affinity toward lubeluzole. Fig. 1E shows the concentration response relationships obtained from inward IhERG elicited at -120 mV using ‘normal’ [K+] (5 mM) and ‘high’ [K+] (94 mM) solutions. From the experimental data in Fig. 
1E we obtained an IC50 of 13 ± 4 nM and a nH of 0.70 ± 0.06 for the inward IhERG in ‘normal’ [K+] solution, and an IC50 of 10.4 ± 1.4 nM and a nH of 0.66 ± 0.07 for the inward IhERG in ‘high’ [K+] solution. Since these values are similar to those found from the concentration-response relationship of hERG outward current inhibition by lubeluzole, we conclude that lubeluzole-induced block of IhERG is not influenced by the concentration or the direction of flux of K+ ions, 
as in the case of other hERG channel blockers (e.g. flecainide [31]).
Effect of lubeluzole moieties on WT hERG channelsStructurally, lubeluzole contains two portions: an aryloxypropranolamine moiety, 
recalling β-adrenergic blockers like propranolol [compound (S)-2, Fig. 1A] and a 1, 3-benzothiazol-2-amine moiety related to riluzole (compound 3, Fig. 1A). Both riluzole 
Fig. 1. A) Structures of lubeluzole and its simplified analogues. B) Pulse protocol and representative hERG currents obtained before (control) and after addition of 100 nM of lubeluzole. C) Time course of lubeluzole-induced hERG tail current inhibition from the same cell shown in (B). D) Concentration-response relationship (mean ± SEM) for block of hERG tail current by lubeluzole, its R enantiomer, and the racemic mixture (n = 5 per data point). E) Concentration response 
relationships obtained from inward IhERG, in the presence of lubelu-zole, using ‘normal’ [K+] (5 mM) and ‘high’ [K+] (94 mM) solutions. F) Concentration-response relationship (mean ± SEM) for block of hERG tail current by BTZ-lub, PPA-lub and BTZ-lub+PPA-lub (n = 5 per data point).
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and propranolol are potent sodium channel blockers. Block of sodium channels caused by 
riluzole seems to be involved in the efficacy of the drug in amyotrophic lateral sclerosis [32]. 
Propranolol blocks sodium channels in a similar manner to local anesthetics [33]. In view of their pharmacological properties, we decided to analyze in detail the effects of the two lubeluzole moieties on hERG channels expressed in HEK cells.The aryloxypropranolamine (PPA-lub) and 1,3-benzothiazol-2-amine (BTZ-lub) moieties were analyzed individually or mixed together and their effects on hERG currents are 
reported in Fig. 1F. Our data show that the IC50 value of lubeluzole is one order of magnitude 
lower than those of the two moieties, i.e. IC50 = 160 ± 12 nM and nH = 1.17 ± 0.22 (BTZ-lub), 
IC50 = 109 ± 16 nM and nH = 1.22 ± 0.19 (PPA-lub), and IC50 = 152 ± 11 nM and nH = 1.40 ± 0.28 (BTZ-lub + PPA-lub). This suggests that lubeluzole binds more effectively to hERG channel with respect to the two moieties, acting individually or mixed in the same solution.
Effect of lubeluzole on hERG activation and deactivationThe voltage-dependence of lubeluzole-induced inhibition was measured on hERG K+ current amplitudes, applying the protocol shown in Fig. 2A. Tail currents were elicited 
by repolarization to -60 mV. Individual tail current amplitudes recorded before (control) or after addition of 10 nM lubeluzole, were normalized to the maximal control amplitude 
and fitted with a Boltzmann function (Fig. 2B).  The presence of lubeluzole caused a left-
shift by -10 mV of the I-V relationship of hERG activation current (Fig. 2C). Moreover, the voltage required for half-maximal activation (V1/2) was leftwards shifted in the presence of 
lubeluzole, from -16 ± 3 mV (control) to -24 ± 1 mV (lubeluzole) (Fig. 2D). Since the V1/2 value of hERG channels is shifted to more negative potentials in the presence of lubeluzole, we conclude that the drug might affect the activation gating of the channel.
Deactivation time constants were obtained by fitting with a single exponential function the currents recorded using the protocol shown in Fig. 2B. As shown in Fig. 2E, lubeluzole slightly increases the deactivation time constant.
Fig. 2. A) Pulse protocol and rep-resentative hERG current traces, in the absence (control) or presence of 10 nM lubeluzole. B) Representa-tive hERG current traces elicited by the voltage protocol shown in the middle panel, testing deactivation currents, in the absence (control) or presence of 10 nM lubeluzole. Current traces before and after ap-plication of lubeluzole are depicted on an expanded time scale (marked as dotted squares in the pulse pro-tocol). C) Normalized (with respect 
to the control currents) I-V relation-ships for activation current mea-
sured during the depolarizing steps, before (control) and after addition (time of incubation ≥ 10 min) of 10 
nM lubeluzole. Error bars for some points are masked by symbols (n ≥ 5 cells per data-point). D) Normalized 
(with respect to the control currents) I-V relationships for current measured at the tail current peaks, before 
(control) and after addition (time of incubation ≥ 10 min) of 10 nM lubeluzole. Error bars for some points 
are masked by symbols (n ≥ 5 cells per data-point). I-V relationships for tail current amplitudes were fitted 
with a Boltzmann function. V1/2 shifted from -16 ± 3 mV (control), to -24 ± 1 mV (P<0.001, paired t-test). 
E) Time constants of deactivation current acquired using the protocol shown in (B). Time constants (τ) of 
deactivation were obtained from monoexponential fits to the decay of tail currents during the 4s- voltage 
step to various potentials. Data are expressed as mean ± SEM (n ≥ 5 per data point). ** P<0.01, *P<0.05 (Two 
way ANOVA followed by Bonferroni test).
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Relationship between lubeluzole block and hERG channel inactivation
IhERG inhibition by drugs can be influenced (or not) by channel inactivation [34- 37, 25].Steady-state inactivation currents were measured following the three-step protocol 
reported in Fig. 3A: channels were inactivated at +60 mV, before short test pulses from -100 
mV to +20 mV were applied, to recover the channels from inactivation. Depolarization to +60 
mV after these test pulses evoked a large outward inactivating current. Fig. 3A shows sample traces of inactivating current IhERG in the absence (control) and in the presence of 10 nM 
lubeluzole. Current amplitudes measured after depolarization to +60 mV were normalized, 
plotted against the corresponding test voltage and fitted by a Boltzmann function (Eq. (3), see online suppl. material). Our data indicate that lubeluzole causes a leftward shift in V1/2 
values of steady-state inactivation, from -55 ± 1 mV in the absence of the drug (control) to 
-70 ± 1 mV in the presence of lubeluzole (Fig. 3B).The effect of lubeluzole on the inactivation time course was also investigated using the 
protocol shown in Fig. 3C. From a holding potential of -80 mV, a 200 ms test pulse to +60 mV 
was applied to inactivate the channel. Moreover, a short pulse to -100 mV and voltage steps 
from -20 mV to +60 mV (300 ms, 10 mV-increments) were applied to elicit a large outward inactivating current.  Fig. 3C shows sample traces of inactivating current IhERG in the absence 
or presence of 10 nM lubeluzole.  Inactivation currents were fitted by a single exponential function to extrapolate time constant values. Fig. 3D shows that the inactivation kinetics of 
hERG channel is significantly accelerated in the presence of lubeluzole.
Effect of mutations in the hERG pore helix and inner cavity on lubeluzole potency
A cluster of three residues (T623, S624 and V625) located in the lower portion of 
the pore helix-selectivity filter region has been reported to be involved in the binding of different drugs to hERG [20, 28]. Moreover, it was shown that hERG channel blockers are able to bind within the channel inner cavity, interacting with one or two aromatic residues of the S6 domain (Tyr652 and Phe656) [38]. In order to determine the roles of these residues 
Fig. 3. hERG channel inactivation. A) Representative hERG current traces, in the absence (control) or presence of 10 nM lubeluzole, elic-ited by the voltage protocol shown in the middle panel, testing steady-state inactivation currents. B) Nor-
malized steady-state I-V inactiva-tion curves before (control) and after application of 10 nM lubelu-zole. Data are expressed as mean ± SEM; error bars for some points are masked by symbols. Solid lines rep-
resent fits with Boltzmann func-
tion. V1/2 shifted from -55 ± 1 mV 
(control), to -70 ± 1 mV (P<0.001, paired t-test; n = 6 cells). Currents traces before and after application of lubeluzole are depicted on an ex-panded time scale (marked as dotted squares in the pulse protocol). C) Pulse protocol and representative 
onset of inactivation currents, in the absence (control) or presence of 10 nM lubeluzole. D) Inactivation 
time constants were derived from currents acquired using the protocol shown in (C), fitted with a single exponential function to the decay of tail currents during the third 300-ms voltage step, and plotted against 
the membrane potential. Data are expressed as mean ± SEM (n ≥ 5 per data point). ***P<0.001 (Two way 
ANOVA followed by Bonferroni test).
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Gualdani et al.: hERG Channel Inhibition by Lubeluzolein lubeluzole block of IhERG, we studied the alanine mutants, S624A, V625A and Y652A, under ‘normal’ [K+] solution. The current associated with these mutants was elicited by the standard voltage protocol shown in Fig. 1B (Fig. 4A). The T623A and F656A mutants were tested under ‘high’ [K+] solution and the current was elicited by a hyperpolarizing step to -120 mV in order to obtain an appreciable inward current transient. Representative traces of T623A and F656A currents in the absence (control) and in the presence of 10 nM lubeluzole are shown in Fig. 4B. Different lubeluzole concentrations were tested and a full concentration–response relationship was constructed for each mutant, as shown in Fig. 4C 
and 4D. The corresponding IC50 values are summarized in Fig. 4E and Table 1, indicating that 
the two aromatic residues F656 and Y652 have a prominent role in lubeluzole block of IhERG.
Binding modes of lubeluzole to different hERG channel states
Lubeluzole interactions with the hERG channel in a putative open inactivated (WT cryo-EM structure) and an open activated state (S631A mutant structure) were analyzed performing docking calculations.  A close-up view of the predicted drug-binding interactions 
is shown in Fig. 5 (WT) and Fig. 6 (S631A). In agreement with mutagenesis data (Fig. 4), 
π-π interactions between the benzothiazole ring and the aromatic moiety of the Y652 side chains were observed in the large majority (> 95%) of all docking poses obtained for both 
WT and S631A channels. Hydrophobic and π-π interactions were frequently observed 
between the difluorophenoxy ring of lubeluzole and the Y652 and F656 side chains. The protonatable nitrogen is located at the center of the strong electronegative cavity, but no 
cation-π interactions were observed in any of the docking poses. Hydrogen bonds to residues 
at the base of the selectivity filter (T623, S624) are not observed, in agreement with the very moderate effects of the respective alanine mutants (Fig. 4E). No differences between the two 
enantiomers were seen (data not shown). Generally, the high affinity of the compound in the 
relative narrow hERG cavities is achieved, via maximizing favorable π-π and hydrophobic 
contacts with Y652 and F656 and lubeluzole.
Fig. 4. A) Representative IhERG 
traces of S624A, V625A and Y652A mutants in the absence (black line) and presence (grey line) of 100 nM lubeluzole. The tail current was evoked by repolarization from 0 to 
-50 mV (same protocol shown in the lower panel of Fig.1B) and was recorded under the ‘normal’ exter-nal solution ([K+] = 5 mM). B) Rep-
resentative IhERG traces of T623A and F656A mutants in the absence (black line) and presence (grey line) of 100 nM lubeluzole. The tail current was evoked by repolariza-
tion from +20 to -120 mV (protocol shown (see online suppl. materi al) in Fig. S1) and was recorded using ‘high’ [K+] solution (94 mM). C) Concentration-response relationships for 
current of T623A, S624A, V625A mutants blocked by lubeluzole. Each value represents mean ± SEM of n ≥ 5 
cells. D) Concentration-response relationships for Y652A and F656A mutants. Each value represents mean 
± SEM of n ≥ 5 cells. E) IC50 values for lubeluzole inhibition of the alanine mutants shown in (A) and (B), 
compared with WT-hERG. Each IC50 was obtained from a concentration–response relationship derived from 
at least four different drug concentrations. ***P<0.001, *P<0.05 (paired t-test); n ≥ 5 for each concentration on each curve.
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DiscussionLubeluzole is a benzothiazole derivative that has shown neuroprotective properties in preclinical models of ischemic stroke. However, clinical research on lubeluzole is now at a standstill, since lubeluzole seems to be associated with the acquired long QT syndrome and ventricular arrhythmias.Our data showed that lubeluzole and its R enantiomer are highly potent inhibitors of hERG 
current with an IC50 value of 12.9 ± 0.7 nM and 11.3 
± 0.8 nM, respectively. In the presence of lubeluzole steady-state activation and inactivation of hERG channel were shifted to more negative potentials and inactivation kinetics was accelerated. Mutations of aromatic 
residues (Y652A and F656A) in the channel inner cavity significantly reduced the inhibitory effect of lubeluzole.Examination of the binding modes obtained from docking calculations suggests 
that lubeluzole binds to the central cavity of the hERG channel and π-π and hydrophobic 
interactions with Y652 and F656 are the main contributors to high affinity binding of this drug.The recently solved hERG cryo-EM structures at near atomic resolution revealed the existence of hydrophobic pouches protruding from the cavity towards the extracellular side, and a possible role for drug-binding was suggested [22]. However, at least for lubeluzole 
these regions do not seem to contribute to drug-binding. Only in < 5% of the docking poses 
the difluorphenoxy moiety of lubeluzole partially protruded into one such hydrophobic 
pocket. No clear state-dependent changes could be observed, when comparing the WT and S631A docking poses, which might be due to the subtle structural differences and the general 
low resolution of the structures (3.7 Å and 4 Å).The presence of low stereoselectivity in hERG blockers is a generally observed feature [40] and may be explained invoking both the plasticity and symmetry of the channel [41]. However, eudismic analysis on bupivacaine enantiomers recently unravelled moderate 
stereoselectivity (stereoselectivity index, SSI = IC50distomer/IC50eutomer ~ 7) [42]. 
While blocking hERG with 1000-fold higher potency than bupivacaine, lubeluzole and its 
enantiomer displayed no stereoselectivity at all (SSI = 0) thus conflicting with the Pfeiffer’s rule [43]. However, the following considerations may help explain the complete lack of stereoselectivity observed in our work (for the sake of simplicity, the discussion will be focused on lubeluzole while all considerations obviously hold for its enantiomer too).First of all, lubeluzole is at least ten times less basic than bupivacaine, with pKa values being 7.14 [8] and 8.17 [44] for lubeluzole and bupivacaine, respectively. Moreover, the protonatable nitrogen of lubeluzole is displaced by one carbon atom from the stereogenic center, unlike bupivacaine, in which the protonatable nitrogen is closer to the stereogenic 
Table 1. Parameters (IC50, nH) derived from the Hill fit of the concen-
tration-response relationships of inhibition of hERG channels (WT, 
T623A, S624A, V625A, Y652A, F656A) by lubeluzole and its moieties. 
For all channel variants, the direction of IhERG and the external K+ con-
centration were specified in brackets
hERG gene Compound IC50 nH WT (out. 5 mM K+) Lub(S) 12.9 ± 0.7 nM 0.84 ± 0.05 WT (inw. 94 mM K+) Lub(S) 10.4  ± 1.4 nM 0.66  ± 0.07  WT (out. 5 mM K+) Lub(R) 11.3 ± 0.8 nM 0.79 ± 0.04  WT (out. 5 mM K+) Lub(R,S) 11.1 ± 0.4 nM 1.10 ± 0.03  WT (out. 5 mM K+) BTZ-Lub 160 ± 12 nM  1.17 ± 0.22  WT (out. 5 mM K+) PPA-Lub 109 ± 16 nM 1.22 ± 0.19 WT (out. 5 mM K+) BTZ-Lub+PPA-Lub 152 ± 11 nM 1.40 ± 0.28 T623A (inw. 94 mM K+) Lub(S) 24 ± 5.0 nM 0.80 ± 0.09 S624A (out. 5 mM K+) Lub(S) 42 ± 16 nM 1.17 ± 0.22 V625A (out. 5 mM K+) Lub(S) 15.4 ± 2.1 nM 0.89 ± 0.11 Y652A (out. 5 mM K+) Lub(S) 350 ± 40 nM 0.98 ± 0.19 F656A (inw. 94 mM K+) Lub(S) 240 ± 50 nM 1.17 ± 0.19  
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center. This consideration could explain why the contribution of the basic group to stereoselective binding should be relatively less important in lubeluzole than in bupivacaine. 
On the other hand, our modeling experiments showed no cation-π interactions in any docking pose.
Secondly, lubeluzole is a relatively flexible compound and its protonatable nitrogen is symmetrically substituted. Thus, even occurring, protonation would not add chiral stereoelectronic demand.Finally, lubeluzole has a relatively symmetric structure roughly depictable as being constituted by two planar portions spaced by an aliphatic linker. The latter, in turn, bears two possibly less relevant pharmacophoric elements, the hydroxyl group and the partially protonated nitrogen atom. Chirality is conferred by the carbinolic group which bears two methylene groups separating the bulkiest molecular moieties. Thus, it may be assumed that the stereogenic requirements imposed by the chirality center are mitigated by the 
Fig. 5. A) Lubeluzole bound to the WT hERG cryo-EM structure. B) Details of the highest scoring binding pose of lubeluzole shown in sticks representation. Hydrogen bonds are depicted as black dotted lines. C) 
2D interaction profiles were generated with PoseView [39]. Green dotted lines indicate π-π interactions between aromatic rings; green solid lines represent hydrophobic interactions. Hydrogen bonds are shown as black dotted lines.
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Fig. 6. A) Lubeluzole bound to the S631A mutant structure. B) Details of the highest scoring binding pose of lubeluzole shown in sticks representation. Hydrogen bonds are depicted as black dotted lines. C) 2D in-
teraction profiles were generated with PoseView [39]. Green dotted lines indicate π-π interactions between aromatic rings; green solid lines represent hydrophobic interactions. Hydrogen bonds are shown as black dotted lines.
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generally related to MW and lipophilicity, with amines being the most redoubtable 
drugs [45]. It comes as no surprise that lubeluzole 
(MW = 434 Da, cLog P = 4.7) was at least 10 thousand times more potent than its constituting fragments 
PPA-lub (MW = 271 Da, cLog P = 3.2) and BTZ-lub 
(MW = 247 Da, cLog P = 2.4) (Fig. 7). Less predictable was the light rise in ligand 
efficiency (LE = 1.37pIC50/HA [46]) observed when passing from the two fragments PPA-lub (LE = 0.21) and BTZ-lub (LE = 0.22) to lubeluzole (LE = 0.26) while generally the contrary is found throughout drug-like molecule space: a decrease in LE is commonly observed with increasing 
MW [46]. Roughly speaking, this means that the non-hydrogen atoms (HA) constituting the 
two fragments contribute more efficiently to the binding when the two moieties are linked 
together to give lubeluzole structure than when acting individually. In fact, lubeluzole 
presented the highest lipophilic ligand efficiency (LLE = pIC50 – cLog P) [47] value (3.2, Fig. 
7), thus indicating that it is the most specific ligand out of the three. In other words, the increase in potency observed when passing from the two fragments to lubeluzole was not merely due to increased lipophilicity. However, both LE and LLE values were relatively low, thus indicating that the driving force of lubeluzole blocking activity is mostly entropic (i. e, 
sustained by van der Waals and hydrophobic contributions [48]). The last statement is in agreement with the observed null stereoselectivity and docking results.
When group efficiency (GE = ∆∆G/∆number of non-hydrogen atoms = ∆1.37pIC50/∆HA) [49, 50] is considered, the 2-aminobenzothiazolic moiety emerged as the most interesting portion (GE = 0.35) since its contribution to lubeluzole potency of block is higher than the one granted by the 3-aryloxy-2-hydroxypropyl portion (GE = 0.32).
ConclusionBoth moieties of lubeluzole contribute to binding. Suitable substituents may be introduced onto both moieties to allow modulation of hERG blocking activity. The benzothiazole ring should be given priority in structure-activity relationship studies.The interaction of drugs with hERG is generally feared as a source of toxicological 
concern due to torsadogenic (i. e. proarrhythmic) potential. In this respect, we propose that the introduction of suitable substituents on one or both constituting portions of lubeluzole 
structure might be exploited to reduce hERG affinity. On the other hand, a therapeutic potential has been suggested for hERG blockers as class III antiarrhythmic and anticancer agents [51]. In this respect, our study let envisage the possibility to develop new lubeluzole 
Fig. 7. Ligand efficiency metric analysis. Group efficiency: GE = 
∆∆G/∆number of non-hydrogen atoms = ∆1.37pIC50/∆HA [48]; ligand 
efficiency: LE = 1.37pIC50/HA [45]; lipophilic ligand efficiency: LLE = 
pIC50 – cLog P [46].
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analogues possibly endowed with more convenient pharmacological profile through both classical structure-activity relationships and computer-assisted studies.
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